doi: 10.3389/fphar.2025.1610512 Received 12 April 2025 Accepted 15 May 2025 Published 30 May 2025 Volume 16 - 2025 Edited by Karuna Rasineni, University of Nebraska Medical Center, United States Reviewed by Asher Rajkumar Rajan, University of Nebraska Medical Center, United States Akash Batta, Dayanand Medical College & Hospital, India Updates Copyright 2025 Li, Huang, Wang, Huang, Luo and Huang
The maximum approved dose of tirzepatide is 15 mg weekly, which represents the highest concentration studied in clinical trials for weight management
Prescribing information (Eli Lilly, 2025)
The overall GLP-1 market continued to expand, growing about 32% year-on-year
Int J Mol Sci (2023) 24(11):9166